New biomarker may predict which pancreatic cancer patients respond to CD40 immunotherapy
(University of Pennsylvania School of Medicine) Inflammation in the blood could serve as a new biomarker to help identify patients with advanced pancreatic cancer who won't respond to the immune-stimulating drugs known as CD40 agonists, suggests a new study from researchers in the Abramson Cancer Center of the University of Pennsylvania published inJCI Insight.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
More News: Cancer | Cancer & Oncology | Immunotherapy | Pancreas | Pancreatic Cancer | Study | University of Pennsylvania